Raised	VBN	raise VBN PennPOS
serum	NN	serum NN PennPOS
levels	NNS	level NNS PennPOS
of	IN	of pp-f NUPOS
IGFBP-1	NN	IGFBP-1 NN PennPOS
and	CC	and cc NUPOS
IGFBP-2	NN	IGFBP-2 NN PennPOS
in	IN	in IN PennPOS
idiopathic	JJ	idiopathic JJ PennPOS
pulmonary	JJ	pulmonary JJ PennPOS
fibrosis	NN	fibrosis NN PennPOS
.	.	. . NUPOS

BACKGROUND	NN	background NN PennPOS
:	:	: : NUPOS
Idiopathic	JJ	idiopathic JJ PennPOS
pulmonary	JJ	pulmonary JJ PennPOS
fibrosis	NN	fibrosis NN PennPOS
(	(	( ( NUPOS
IPF	NN	IPF NN PennPOS
)	)	) ) NUPOS
is	VBZ	be vbz NUPOS
a	DT	a dt NUPOS
chronic	JJ	chronic JJ PennPOS
lung	NN	lung NN PennPOS
disorder	NN	disorder NN PennPOS
of	IN	of pp-f NUPOS
unknown	JJ	unknown JJ PennPOS
origin	NN	origin NN PennPOS
,	,	, , NUPOS
which	WDT	which r-crq NUPOS
ultimately	RB	ultimate av-j NUPOS
leads	VBZ	lead VBZ PennPOS
to	TO	to p-acp NUPOS
death	NN	death NN PennPOS
.	.	. . NUPOS

Several	JJ	several JJ PennPOS
growth	NN	growth NN PennPOS
factors	NNS	factor NNS PennPOS
such	JJ	such JJ PennPOS
as	IN	as c-acp NUPOS
IGFs	NNS	igf NNS PennPOS
(	(	( ( NUPOS
insulin-like-growth	JJ	insulin-like-growth JJ PennPOS
factor	NN	factor NN PennPOS
)	)	) ) NUPOS
and	CC	and cc NUPOS
IGFBPs	NNS	igfbp NNS PennPOS
(	(	( ( NUPOS
insulin	NN	insulin NN PennPOS
like	IN	like IN PennPOS
growth	NN	growth NN PennPOS
factor	NN	factor NN PennPOS
binding	NN	binding NN PennPOS
proteins	NNS	protein NNS PennPOS
)	)	) ) NUPOS
seem	VBP	seem VBP PennPOS
to	TO	to p-acp NUPOS
take	VB	take VBP PennPOS
part	NN	part NN PennPOS
to	TO	to p-acp NUPOS
the	DT	the dt NUPOS
pathogenesis	NN	pathogenesis NN PennPOS
.	.	. . NUPOS

We	PRP	we pns12 NUPOS
evaluated	VBD	evaluate VBD PennPOS
IGFs	NNS	igf NNS PennPOS
and	CC	and cc NUPOS
IGFBPs	NNS	igfbp NNS PennPOS
in	IN	in IN PennPOS
serum	NN	serum NN PennPOS
from	IN	from pp NUPOS
patients	NNS	patient NNS PennPOS
with	IN	with pp NUPOS
IPF	NN	IPF NN PennPOS
and	CC	and cc NUPOS
healthy	JJ	healthy JJ PennPOS
subjects	NNS	subject NNS PennPOS
including	VBG	include VBG PennPOS
24	CD	24 crd NUPOS
untreated	JJ	untreated JJ PennPOS
IPF	NN	IPF NN PennPOS
and	CC	and cc NUPOS
26	CD	26 crd NUPOS
IPF	NN	IPF NN PennPOS
receiving	VBG	receive VBG PennPOS
anti-fibrotic	JJ	anti-fibrotic JJ PennPOS
therapy	NN	therapy NN PennPOS
and	CC	and cc NUPOS
to	TO	to p-acp NUPOS
compare	VB	compare VBP PennPOS
them	PRP	they pno32 NUPOS
with	IN	with pp NUPOS
healthy	JJ	healthy JJ PennPOS
subjects	NNS	subject NNS PennPOS
.	.	. . NUPOS

METHODS	NNS	method NNS PennPOS
:	:	: : NUPOS
Serum	NN	serum NN PennPOS
of	IN	of pp-f NUPOS
50	CD	50 CD PennPOS
idiopathic	JJ	idiopathic JJ PennPOS
pulmonary	JJ	pulmonary JJ PennPOS
fibrosis	NN	fibrosis NN PennPOS
and	CC	and cc NUPOS
55	CD	55 CD PennPOS
healthy	JJ	healthy JJ PennPOS
subjects	NNS	subject NNS PennPOS
(	(	( ( NUPOS
HS	NN	HS NN PennPOS
)	)	) ) NUPOS
were	VBD	be vbd NUPOS
analysed	VBN	analyse VBN PennPOS
by	IN	by IN PennPOS
ELISA	NN	elisa NN PennPOS
for	IN	for c-acp NUPOS
IGFs	NNS	igf NNS PennPOS
and	CC	and cc NUPOS
IGFBPs	NNS	igfbp NNS PennPOS
,	,	, , NUPOS
TGF-b	NN	TGF-b NN PennPOS
and	CC	and cc NUPOS
KL-6	NN	KL-6 NN PennPOS
,	,	, , NUPOS
the	DT	the dt NUPOS
latter	JJ	latter JJ PennPOS
being	VBG	be vbg NUPOS
tested	VBN	test VBN PennPOS
as	IN	as c-acp NUPOS
positive	JJ	positive JJ PennPOS
control	NN	control NN PennPOS
in	IN	in IN PennPOS
IPF	NN	IPF NN PennPOS
.	.	. . NUPOS

RESULTS	NNS	result NNS PennPOS
:	:	: : NUPOS
Serum	NN	serum NN PennPOS
levels	NNS	level NNS PennPOS
of	IN	of pp-f NUPOS
IGFBP-1	NN	IGFBP-1 NN PennPOS
and	CC	and cc NUPOS
IGFBP-2	NN	IGFBP-2 NN PennPOS
and	CC	and cc NUPOS
KL-6	NN	KL-6 NN PennPOS
were	VBD	be vbd NUPOS
significantly	RB	significant av-j NUPOS
higher	JJR	high JJR PennPOS
in	IN	in IN PennPOS
the	DT	the dt NUPOS
IPF	NN	IPF NN PennPOS
group	NN	group NN PennPOS
than	IN	than cs NUPOS
in	IN	in IN PennPOS
the	DT	the dt NUPOS
healthy	JJ	healthy JJ PennPOS
subjects	NNS	subject NNS PennPOS
(	(	( ( NUPOS
p	NN	p NN PennPOS
<	JJR	< JJR PennPOS
0.05	CD	0.05 CD PennPOS
,	,	, , NUPOS
p	NN	p NN PennPOS
<	JJR	< JJR PennPOS
0.001	CD	0.001 CD PennPOS
and	CC	and cc NUPOS
p	NN	p NN PennPOS
<	JJR	< JJR PennPOS
0.0001	CD	0.0001 CD PennPOS
respectively	RB	respective av-j NUPOS
)	)	) ) NUPOS
while	IN	while cs NUPOS
the	DT	the dt NUPOS
picture	NN	picture NN PennPOS
was	VBD	be vbd NUPOS
inversed	JJ	inversed JJ PennPOS
regarding	VBG	regard VBG PennPOS
IGFs	NNS	igf NNS PennPOS
.	.	. . NUPOS

By	IN	by IN PennPOS
contrast	NN	contrast NN PennPOS
there	EX	there pc-acp NUPOS
was	VBD	be vbd NUPOS
no	DT	no dx NUPOS
significant	JJ	significant JJ PennPOS
difference	NN	difference NN PennPOS
between	IN	between IN PennPOS
the	DT	the dt NUPOS
groups	NNS	group NNS PennPOS
with	IN	with pp NUPOS
respect	NN	respect NN PennPOS
to	TO	to p-acp NUPOS
TGF-b	NN	TGF-b NN PennPOS
.	.	. . NUPOS

IGFBP-2	NN	IGFBP-2 NN PennPOS
was	VBD	be vbd NUPOS
significantly	RB	significant av-j NUPOS
reduced	VBN	reduce VBN PennPOS
in	IN	in IN PennPOS
the	DT	the dt NUPOS
patients	NNS	patient NNS PennPOS
with	IN	with pp NUPOS
specific	JJ	specific JJ PennPOS
anti-fibrotic	JJ	anti-fibrotic JJ PennPOS
therapy	NN	therapy NN PennPOS
pirfenidone	NN	pirfenidone NN PennPOS
and	CC	and cc NUPOS
nintedanib	NN	nintedanib NN PennPOS
compared	VBN	compare VBN PennPOS
to	TO	to p-acp NUPOS
untreated	JJ	untreated JJ PennPOS
patients	NNS	patient NNS PennPOS
(	(	( ( NUPOS
p	NN	p NN PennPOS
<	JJR	< JJR PennPOS
0.05	CD	0.05 CD PennPOS
)	)	) ) NUPOS
but	CC	but cc-acp NUPOS
still	RB	still av NUPOS
significantly	RB	significant av-j NUPOS
elevated	JJ	elevated JJ PennPOS
in	IN	in IN PennPOS
comparison	NN	comparison NN PennPOS
to	TO	to p-acp NUPOS
HS	NN	HS NN PennPOS
(	(	( ( NUPOS
p	NN	p NN PennPOS
<	JJR	< JJR PennPOS
0.001	CD	0.001 CD PennPOS
)	)	) ) NUPOS
.	.	. . NUPOS

CONCLUSION	NN	conclusion NN PennPOS
:	:	: : NUPOS
Serum	NN	serum NN PennPOS
IGFBP-1	NN	IGFBP-1 NN PennPOS
and	CC	and cc NUPOS
-2	CD	-2 CD PennPOS
are	VBP	be vbb NUPOS
increased	VBN	increase VBN PennPOS
in	IN	in IN PennPOS
idiopathic	JJ	idiopathic JJ PennPOS
pulmonary	JJ	pulmonary JJ PennPOS
fibrosis	NN	fibrosis NN PennPOS
and	CC	and cc NUPOS
IGFBP-2	NN	IGFBP-2 NN PennPOS
may	MD	may vmb NUPOS
be	VB	be vbi NUPOS
reduced	VBN	reduce VBN PennPOS
by	IN	by IN PennPOS
anti-fibrosing	JJ	anti-fibrosing JJ PennPOS
therapy	NN	therapy NN PennPOS
.	.	. . NUPOS

IGFBPs	NNS	igfbp NNS PennPOS
may	MD	may vmb NUPOS
be	VB	be vbi NUPOS
promising	JJ	promising JJ PennPOS
biomarkers	NNS	biomarker NNS PennPOS
in	IN	in IN PennPOS
IPF	NN	IPF NN PennPOS
.	.	. . NUPOS

